Patents Assigned to Cora Healthcare, Inc.
  • Protocol for risk stratification of ischemic events and optimized individualized treatment
    Patent number: 8076144
    Abstract: A hemostasis analyzer, such as the Thrombelastograph® (TEG®) hemostasis analyzer is utilized to measure continuously in real time, the hemostasis process from the initial fibrin formation, through platelet-fibrin interaction and lysis to generate blood hemostasis parameters. The measured blood hemostasis parameters permit preparation of an individualized assessment of ischemic event risk and individualized treatment of a subject.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: December 13, 2011
    Assignee: Cora Healthcare, Inc.
    Inventor: Eli Cohen
  • Protocol for monitoring direct thrombin inhibition
    Patent number: 8008086
    Abstract: A hemostasis analyzer, such as the Thrombelastograph® (TEG®) hemostasis analyzer is utilized to measure continuously in real time, the hemostasis process from the initial fibrin formation, through platelet-fibrin interaction and lysis to generate blood hemostasis parameters. The measured blood hemostasis parameters permit evaluation of hemostasis therapies including anticoagulation therapies such as direct thrombin inhibition therapies.
    Type: Grant
    Filed: May 24, 2007
    Date of Patent: August 30, 2011
    Assignee: Cora Healthcare, Inc.
    Inventors: Eli Cohen, Roslyn Cohen
  • Protocol for Risk Stratification of Ischemic Events and Optimized Individualized Treatment
    Publication number: 20110117586
    Abstract: A hemostasis analyzer, such as the Thrombelastograph® (TEG®) hemostasis analyzer is utilized to measure continuously in real time, the hemostasis process from the initial fibrin formation, through platelet-fibrin interaction and lysis to generate blood hemostasis parameters. The measured blood hemostasis parameters permit preparation of an individualized assessment of ischemic event risk and individualized treatment of a subject.
    Type: Application
    Filed: January 21, 2011
    Publication date: May 19, 2011
    Applicant: CORA HEALTHCARE, INC.
    Inventor: Eli Cohen
  • Protocol for risk stratification of ischemic events and optimized individualized treatment
    Patent number: 7939329
    Abstract: A hemostasis analyzer, such as the Thrombelastograph® (TEG®) hemostasis analyzer is utilized to measure continuously in real time, the hemostasis process from the initial fibrin formation, through platelet-fibrin interaction and lysis to generate blood hemostasis parameters. The measured blood hemostasis parameters permit preparation of an individualized assessment of ischemic event risk and individualized treatment of a subject.
    Type: Grant
    Filed: October 26, 2009
    Date of Patent: May 10, 2011
    Assignee: Cora Healthcare, Inc.
    Inventor: Eli Cohen
  • Protocol and apparatus for determining heparin-induced thrombocytopenia
    Patent number: 7811792
    Abstract: A hemostasis analyzer, such as the Thrombelastograph® (TEG®) hemostasis analyzer is utilized to measure continuously in real time, the hemostasis process from the initial fibrin formation, through platelet-fibrin interaction and lysis to generate blood hemostasis parameters. The measured blood hemostasis parameters permit determination of heparin-induced thrombocytopenia II complex (HiT II).
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: October 12, 2010
    Assignee: Cora Healthcare, Inc.
    Inventors: Eli Cohen, Roslyn Cohen
  • Protocol for risk stratification of ischemic events and optimized individualized treatment
    Patent number: 7754489
    Abstract: A hemostasis analyzer, such as the Thrombelastograph® (TEG®) hemostasis analyzer is utilized to measure continuously in real time, the hemostasis process from the initial fibrin formation, through platelet-fibrin interaction and lysis to generate blood hemostasis parameters. The measured blood hemostasis parameters permit preparation of an individualized assessment of ischemic event risk and individualized treatment of a subject.
    Type: Grant
    Filed: December 31, 2008
    Date of Patent: July 13, 2010
    Assignee: Cora Healthcare, Inc.
    Inventor: Eli Cohen
  • Protocol For Risk Stratification of Ischemic Events and Optimized Individualized Treatment
    Publication number: 20100041081
    Abstract: A hemostasis analyzer, such as the Thrombelastograph® (TEG®) hemostasis analyzer is utilized to measure continuously in real time, the hemostasis process from the initial fibrin formation, through platelet-fibrin interaction and lysis to generate blood hemostasis parameters. The measured blood hemostasis parameters permit preparation of an individualized assessment of ischemic event risk and individualized treatment of a subject.
    Type: Application
    Filed: October 26, 2009
    Publication date: February 18, 2010
    Applicant: CORA HEALTHCARE, INC.
    Inventor: Eli Cohen